IP
ENFN

Interval Partners’s Enfusion, Inc. ENFN Stock Holding History

Interval Partners’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-288,379
Closed -$2.97M – 525
2024
Q4 		$2.97M Buy
+288,379
New +$2.79M 0.06% 234

Other funds holding ENFN

FMC
FTV Management Company San Francisco, California $514M AUM 4.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
LECM
Lead Edge Capital Management New York $550M AUM 11.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Interval Partners's ENFN Position: Q1 2025 in Review

Interval Partners sold out of Enfusion, Inc. (ENFN) in Q1 2025, closing a stake of 288,379 shares — an estimated $2.97M sold.

Interval Partners first reported a position in ENFN in Q4 2024 and held it in 1 quarter. The position peaked at $2.97M in Q4 2024. 132 funds tracked by Wall St. Rank hold ENFN as of Q1 2025.

  • Interval Partners reported no remaining Enfusion, Inc. position as of Q1 2025 after selling out during the quarter.
  • Interval Partners sold 288,379 Enfusion, Inc. shares in Q1 2025, an estimated $2.97M.
  • Interval Partners first reported a position in Enfusion, Inc. in Q4 2024 and held it in 1 quarter.
  • Interval Partners's Enfusion, Inc. position peaked at $2.97M in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q1 2025.

Based on Interval Partners's 13F filing for Q1 2025, filed 15 May 2025.